study focused patients aged 18 65 schizophrenia diagnosis , requiring treatment due inadequate response intolerance previous medication . Exclusion criteria specific , hypersensitivity study drugs severe somatic diseases . Patients cannabis abuse excluded . Tardive dyskinesia criterion exclusion monitored . total 136 patients 149 initially recruited included final analysis , 63 conventional antipsychotic group 73 new antipsychotic group . Data collected various scales , including PSP , SF-36 quality life , Mini-ICF-Rating symptoms . study employed double-blind , randomized design across 14 centers Germany , patients assessed multiple points 24 weeks . primary endpoint assessment AUC values SF-36 CGI , missing data imputed using LOCF . Secondary analyses exploratory .